Why Is AMYLYX PHARMACEUTICA (AMLX) Stock Moving Today?

AMLX stock is moving lower today, down 10% over the past 8 sessions as the stock trades from $38.60 to $34.74. The decline follows recent insider sales and ongoing pressure from broader market dynamics. The stock remains unprofitable with a trailing twelve-month revenue decline of 100.3% and an EPS of -1.43.

What Happened

Amylyx is facing a period of investor caution following a recent insider sale by Gina Mazzariello, who sold shares on July 9, 2026. This sale is part of a broader pattern, with no insider buys and one insider sale totaling $539K in the last 90 days. Meanwhile, the company has drawn attention for its GLP-1 drug candidate, which is seen as a potential threat to Eli Lilly’s market leadership. However, this has not yet translated into improved fundamentals for Amylyx, which remains unprofitable and has seen its stock price fall sharply from its 52-week high of $41.14.

What The Data Shows

The stock has moved -10.0% over the last 8 sessions, reflecting a broader bearish trend. The recent insider sale adds to the pressure, as does the company’s weak financial performance. Despite analyst optimism from Guggenheim and Mizuho, which have raised price targets to $57 and $42 respectively, the market has not responded positively. The company also recently completed a $500 million public offering, but this has not yet stabilized the stock.

What To Watch

Investors should continue to monitor the breadth of analyst coverage and any further insider activity. The company’s progress with its GLP-1 drug candidate could also influence future stock performance.